Expression and Mutational Analysis of c-kit in Ovarian Surface Epithelial Tumors.
10.3346/jkms.2006.21.1.81
- Author:
Dong Ja KIM
1
;
Myung Hoon LEE
;
Tae In PARK
;
Han Ik BAE
Author Information
1. Department of Pathology, Fatima Hospital, Daegu, Korea. dongja@fatima.or.k
- Publication Type:Original Article
- Keywords:
Proto-Oncogene Proteins c-kit;
Ovarian Neoplasms;
Mutation;
imatinib
- MeSH:
Adult;
Aged;
Cystadenocarcinoma, Mucinous/genetics/metabolism/pathology;
Cystadenoma, Mucinous/genetics/metabolism/pathology;
Cystadenoma, Serous/genetics/metabolism/pathology;
DNA Mutational Analysis;
DNA, Neoplasm/chemistry/genetics;
Epithelial Cells/chemistry/metabolism/pathology;
Female;
Gene Expression Regulation, Neoplastic;
Humans;
Immunohistochemistry;
Middle Aged;
Mutation;
Ovarian Neoplasms/genetics/metabolism/*pathology;
Polymerase Chain Reaction;
Polymorphism, Single-Stranded Conformational;
Proto-Oncogene Proteins c-kit/biosynthesis/*genetics
- From:Journal of Korean Medical Science
2006;21(1):81-85
- CountryRepublic of Korea
- Language:English
-
Abstract:
Coexpression of Kit ligand and c-kit has been reported in some gynecologic tumors. To determine whether imatinib mesylate is useful in ovarian epithelial tumors, we performed immunohistochemical and mutational analysis. The cases consisted of 33 cases, which included 13 serous cystadenocarcinomas, 1 borderline serous tumor, 8 mucinous cystadenocarcinomas, 6 borderline mucinous tumors and 5 clear cell carcinomas. Five cases of serous cystadenoma and 5 cases of mucinous cystadenoma were also included. In the immunohistochemical study, 3 cases (3/6, 50%) of borderline mucinous cystic tumor and two cases (2/8, 25%) of mucinous cystadenocarcinoma show positive staining for KIT protein. Only one case (1/13, 7.7%) of serous cystadenocarcinoma had positive staining. On mutational analysis, no mutation was identified at exon 11. However, two cases of borderline mucinous tumors and one case of mucinous cystadenocarcinoma had mutations at exon 17. In these cases, the immunohistochemistry also shows focal positive staining at epithelial component. Although, KIT protein expression showed higher incidence in mucinous tumors than serous tumors, they lack KIT-activating mutations in exon 11. Thus, ovarian surface epithelial tumors are unlikely to respond to imatinib mesylate.
